S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
NCT00003120
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known whether giving paclitaxel for a shorter period of time is as effective as a standard course of treatment for advanced ovarian cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel given for 3 months with that of paclitaxel given for 12 months in treating patients who have stage III or stage IV ovarian, fallopian tube, or pr... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/07/2014
Locations: Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma +1 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
TAXUS PERSEUS Workhorse
NCT00484315
Completed
The purpose of the TAXUS PERSEUS Workhorse trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 28 mm in length in native coronary arteries of 2.75 mm to 4.0 mm diameter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2014
Locations: Oklahoma Foundation for Cardiovascular Research, Oklahoma City, Oklahoma
Conditions: Coronary Artery Disease
Register for Updates
TAXUS PERSEUS Small Vessel
NCT00489541
Completed
The purpose of the TAXUS PERSEUS Small Vessel trial is to evaluate the safety and efficacy of the next-generation Boston Scientific TAXUS paclitaxel-eluting coronary stent system (TAXUS® ElementTM) for the treatment of de novo atherosclerotic lesions of up to 20 mm in length in native coronary arteries of ≥ 2.25 mm to \< 2.75 mm diameter.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/24/2014
Locations: Oklahoma Foundation for Cardiovascular Research, Oklahoma City, Oklahoma
Conditions: Coronary Artery Disease
Register for Updates
Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers
NCT00666991
Completed
The purpose of this study is to evaluate the safety, pharmacokinetics and preliminary efficacy of an intraperitoneally administered suspension of nanoparticulate paclitaxel in patients with refractory malignancies principally confined to the peritoneal cavity.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2014
Locations: Peggy and Charles Stephenson Oklahoma Cancer Center, Oklahoma City, Oklahoma
Conditions: Peritoneal Neoplasms
Register for Updates
A Trial of Paclitaxel and Bevacizumab vs. Gemcitabine, Paclitaxel, and Bevacizumab in Advanced Breast Cancer
NCT00320541
Completed
This study will compare the cancer response to both treatments for locally advanced or metastatic breast cancer
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/15/2013
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Oklahoma City, Oklahoma
Conditions: Breast Cancer
Register for Updates
Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer
NCT00002568
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or combining chemotherapy with surgery may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy consisting of paclitaxel and cisplatin with or without surgery in treating patients with stage III ovarian epithelial cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
07/08/2013
Locations: University of Oklahoma College of Medicine, Oklahoma City, Oklahoma
Conditions: Ovarian Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer
NCT00003378
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients with previously untreated stage III or stage IV ovarian or primary peritoneal cancer.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
07/08/2013
Locations: University of Oklahoma College of Medicine, Oklahoma City, Oklahoma +1 locations
Conditions: Ovarian Cancer, Primary Peritoneal Cavity Cancer
Register for Updates
Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT00003691
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy consisting of doxorubicin and cisplatin with or without paclitaxel and G-CSF in treating patients who have stage III, stage IV, or recurrent endometrial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2013
Locations: University of Oklahoma College of Medicine, Oklahoma City, Oklahoma +1 locations
Conditions: Endometrial Cancer
Register for Updates
Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer
NCT00002888
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether cisplatin plus fluorouracil are more effective than paclitaxel plus cisplatin in treating patients with advanced head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating patients with advanced head and neck cance... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma +1 locations
Conditions: Head and Neck Cancer
Register for Updates
Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
NCT00006484
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of carboplatin plus paclitaxel with or without tirapazamine in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma +1 locations
Conditions: Lung Cancer
Register for Updates
Paclitaxel in Treating Patients With Advanced, Refractory, or Recurrent Cervical or Vaginal Cancer
NCT00002562
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with advanced, refractory, or recurrent cervical or vaginal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
06/19/2013
Locations: University of Oklahoma College of Medicine, Oklahoma City, Oklahoma
Conditions: Cervical Cancer, Vaginal Cancer
Register for Updates
S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00028769
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Androgens can stimulate the growth of prostate cancer cells. Drugs such as goserelin, leuprolide, flutamide, or bicalutamide may stop the adrenal glands from producing androgens. Combining chemotherapy with hormone therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus hormone therapy in treating patients who have... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/12/2013
Locations: Oklahoma University Medical Center, Oklahoma City, Oklahoma
Conditions: Prostate Cancer
Register for Updates